...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

Your numbers make good sense relative to what has been revealed at conferences up through early this year.  So somewhere around 5% annual MACE (3 pt) for the trial.

That seems like a nice low number......

(I know there are a lot of caveats...)

Share
New Message
Please login to post a reply